Observational studyJapanese journal of clinical oncology2025
A questionnaire-based cross-sectional study on neuropathic pain in patients with cancer in Japan.
Observational study in Japanese journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Author's reply to "A questionnaire-based cross-sectional study on neuropathic pain in patients with cancer in Japan: a deeper look into potential confounding variables".Japanese journal of clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSome patients with cancer experience cancer-related neuropathic pain. This study investigated the prevalence of possible neuropathic pain in patients with cancer.
methodsThis observational, cross-sectional, questionnaire-based study recruited adult participants with stage ≥II cancer in Japan between June and November 2024. The primary endpoint was the proportion of participants with suspected neuropathic pain (Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale [S-LANSS] score ≥ 12 points). Secondary endpoints included pain scores (11-point numeric rating scale [NRS]), communication with healthcare professionals, impact on daily activities, and quality of life (QoL) per the EQ-5D-5L.
resultsResponses from 713 participants were analyzed. Of those, 230 participants (32.3%) reported cancer-related pain and 53 (7.4%) had suspected neuropathic pain. Among participants with suspected neuropathic pain, the mean ± standard deviation (SD) pain intensity (NRS) was 5.1 ± 2.7. Over one-third of participants (37.7% [20/53]) with suspected neuropathic pain reported that no healthcare provider had asked about cancer pain before they sought a consultation, 60.4% (32/53) wished their healthcare provider had noticed their pain sooner, 69.8% (37/53) could no longer perform some daily activities due to cancer pain, and 98.1% (52/53) thought their pain needed to be adequately treated for them to live their life going forward. QoL was lower among participants with suspected neuropathic pain versus the overall population (EQ-5D-L mean ± SD: 0.6065 ± 0.2518 vs 0.8204 ± 0.1788).
conclusionsThese findings suggest that pain assessment earlier in the cancer treatment process than standard may improve pain management for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.